GNBT Generex Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : GNBT Generex

GNBT 0.00

Jan 27 4:00 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

From: manny t	11/9/2006 12:13:57 PM
	of 310

GNBT, Generex Biotechnology Granted New Drug Delivery Patent in Australia Thursday November 9, 12:06 pm ET TORONTO--(MARKET WIRE)--Nov 9, 2006 -- Generex Biotechnology Corporation (NASDAQ:GNBT - News), the leader in drug delivery for metabolic diseases through the inner lining of the mouth, announced today that it has been granted a new Australian Patent by IP Australia's Patent Office titled "Pharmaceutical Compositions for Buccal and Pulmonary Application." The patent covers claims to the composition, processes, and methodologies for the delivery of macromolecules via the buccal cavity of the mouth. ADVERTISEMENT The patent, an extant United States Patent held by the Company, relates to an improved pharmaceutical composition comprising macromolecule pharmaceuticals in micellar form which are particularly effective in buccal and pulmonary applications. The invention relates to methods for preparing and using these pharmaceutical compositions. Methods for enhancing the rate of absorption of a macromolecular pharmaceutical agent are also disclosed. The Company currently holds an aggregate of 79 patents worldwide (20 of which are United States Patents) and has an aggregate of 61 patent applications pending in various jurisdictions.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next